Oct 10, 2013

Posted by in Featured, Stock Market News | 0 Comments

Eye-Catching Stocks: Himax Technologies, Inc. (ADR) (NASDAQ:HIMX), Colonial Properties Trust Inc (NYSE:CLP), Immunomedics (NASDAQ:IMMU) and DragonWave (NASDAQ:DRWI)

Eye-Catching Stocks: Himax Technologies, Inc. (ADR) (NASDAQ:HIMX), Colonial Properties Trust Inc (NYSE:CLP), Immunomedics (NASDAQ:IMMU) and DragonWave (NASDAQ:DRWI)

DragonWave (NASDAQ:DRWI) declared EPS in-line, below average revenues. The company reported second quarter (Aug) loss of $0.28 per share, meeting with the Capital IQ Consensus Estimate consensus of ($0.28); revenues declined 42.4% year/year to $25.45 million, as compared to $28.82 million consensus.

Colonial Properties Trust Inc (NYSE:CLP) settled -0.53% lower at $22.37 on high volume of 18.95 million shares during the last trading day. The stock has its 12-month high at $25.27 and 52-week low price was $19.79.

Colonial Properties Trust (the Trust) is a multifamily-focused self-administered equity real estate investment trust (REIT) that owns, operates and develops multifamily communities primarily located in the Sunbelt region of the United States.

Himax Technologies, Inc. (ADR) (NASDAQ:HIMX) saw its price rise on below-normal volume, as 10.87 million shares changed hands, when compared with its average daily volume of 13.37 million shares. The stock rallied 1.29% to end at $10.21.

Himax Technologies, Inc. operates as an IC design house with LCD manufacturing capability. The Company focuses on display IC products for display devices and offers LCD technical consulting to customers to provide them with value-added technical support and integrated solutions.

Immunomedics (NASDAQ:IMMU) declares ending of a deal and return of worldwide rights to veltuzumab for all non-cancer indications. The company declared that it has got notification from Takeda Pharmaceutical Company (TKPYY) of the ending of the licensing deal inked between Nycomed GmbH and Immunomedics for the worldwide rights to veltuzumab, the civilized anti-CD20 antibody, for all non-cancer indications.

Comments are closed.